G-protein coupled estrogen receptor 1 (GPER1) expression improves survival of glioblastoma patients depending on sex and age: biological mechanisms and epigenetic regulation
Abstract
Introduction In 2021, WHO classification of brain tumors adopted an integrated approach, combining histopathological features with key molecular alterations, notably redefining astrocytoma and glioblastoma entities. Among gliomas, glioblastoma has the worst prognosis, with a median patient survival rate of no more than 15 months. To date, no treatment is effective and there is no targeted therapy available. Recent research underscores the influence of sex and sex hormones in gliomagenesis, development and response to treatment. Indeed, glioblastoma exhibit sex-based disparities in adults, with a higher incidence of these tumors and shorter survival in males compared to females. Sex differences tend to narrow in older populations, suggesting that beside genetic sex or acquired gender-biased specificities, sex hormones play a significant role in this difference. Among the key hormone receptors potentially involved, we focused on GPER, the membrane g-coupled estrogen receptor. Methods Expression, methylation and clinical data from TCGA-LGG and TCGA-GBM datasets were reclassified according to WHO 2021. GPER1 expression level was correlated to patient overall survival and methylation status of the GPER1 locus. Underlying mechanisms were unraveled in vitro by transcriptomic and functional analyses of GPER-overexpressing cells. Results A high expression of GPER1 predicted overall survival depending on age and sex, especially for females aged less than 55 years. Functional analysis of GPER1 -correlated genes indicated that GPER1 high expression is associated with cell cycle impairment. In vitro , GPER protein overexpression impaired U251 cell proliferation, which confirmed the benefice of GPER1 high expression against glioblastoma. Since methylation of GPER1 locus was previously shown to control its expression in other cancers, we finally identified 3 CpG sites whose methylation level were inversely correlated with GPER1 expression. Interestingly, the combined low methylation level of these 3 CpG sites is associated with prolonged overall survival in females under the age of 55, suggesting that methylation at these loci may contribute to GPER1 expression control in glioblastoma. Conclusion The present findings identify a potential mechanism of GPER1 regulation in glioblastoma and suggest that GPER could be a therapeutic target of interest, notably for non-menopaused women.
Related
- Epigenetic regulation of DPP4 receptor expression by NONO enables replication of MERS-CoV
- Epigenetic and mitochondrial regulation in kidney disease: emerging mechanisms and therapeutic opportunities
- Epigenetic Regulation and Gut Microbiota Dysbiosis in Age-Related Macular Degeneration
- CTR1-mediated copper uptake orchestrates metabolic-epigenetic regulation of pathogenic TH17 cells in autoimmune disease
- Epigenetic regulation of cancer drivers and EMT revealed by genome-wide methylome profiling in NSCLC
BibTeX
@article{gantner2026gprotein,
title = {{G-protein coupled estrogen receptor 1 (GPER1) expression improves survival of glioblastoma patients depending on sex and age: biological mechanisms and epigenetic regulation}},
author = {Alice Gantner and Laetitia Soudre-Bau and Yann Bailly and Alicia Chateau and Fabien Rech and Hélène Dubois-Pot-Schneider and Hélène Dumond},
journal = {Frontiers in Endocrinology},
year = {2026},
month = sep,
doi = {10.3389/fendo.2026.1923928},
url = {https://hal.science/hal-05842175v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - G-protein coupled estrogen receptor 1 (GPER1) expression improves survival of glioblastoma patients depending on sex and age: biological mechanisms and epigenetic regulation
AU - Alice Gantner
AU - Laetitia Soudre-Bau
AU - Yann Bailly
AU - Alicia Chateau
AU - Fabien Rech
AU - Hélène Dubois-Pot-Schneider
AU - Hélène Dumond
PY - 2026
DA - 2026/09/25
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1923928
UR - https://hal.science/hal-05842175v1
AB - Introduction In 2021, WHO classification of brain tumors adopted an integrated approach, combining histopathological features with key molecular alterations, notably redefining astrocytoma and glioblastoma entities. Among gliomas, glioblastoma has the worst prognosis, with a median patient survival rate of no more than 15 months. To date, no treatment is effective and there is no targeted therapy available. Recent research underscores the influence of sex and sex hormones in gliomagenesis, development and response to treatment. Indeed, glioblastoma exhibit sex-based disparities in adults, with a higher incidence of these tumors and shorter survival in males compared to females. Sex differences tend to narrow in older populations, suggesting that beside genetic sex or acquired gender-biased specificities, sex hormones play a significant role in this difference. Among the key hormone receptors potentially involved, we focused on GPER, the membrane g-coupled estrogen receptor. Methods Expression, methylation and clinical data from TCGA-LGG and TCGA-GBM datasets were reclassified according to WHO 2021. GPER1 expression level was correlated to patient overall survival and methylation status of the GPER1 locus. Underlying mechanisms were unraveled in vitro by transcriptomic and functional analyses of GPER-overexpressing cells. Results A high expression of GPER1 predicted overall survival depending on age and sex, especially for females aged less than 55 years. Functional analysis of GPER1 -correlated genes indicated that GPER1 high expression is associated with cell cycle impairment. In vitro , GPER protein overexpression impaired U251 cell proliferation, which confirmed the benefice of GPER1 high expression against glioblastoma. Since methylation of GPER1 locus was previously shown to control its expression in other cancers, we finally identified 3 CpG sites whose methylation level were inversely correlated with GPER1 expression. Interestingly, the combined low methylation level of these 3 CpG sites is associated with prolonged overall survival in females under the age of 55, suggesting that methylation at these loci may contribute to GPER1 expression control in glioblastoma. Conclusion The present findings identify a potential mechanism of GPER1 regulation in glioblastoma and suggest that GPER could be a therapeutic target of interest, notably for non-menopaused women.
SN - 1664-2392
ER -